Clinical Research Directory
Browse clinical research sites, groups, and studies.
Quetiapine to Reduce Post Concussive Syndrome After Mild Traumatic Brain Injury (mTBI)
Sponsor: Foundation for Advancing Veterans' Health Research
Summary
A two site, 2-arm, Phase III randomized pragmatic clinical trial evaluating the effectiveness of quetiapine monotherapy in comparison to Treatment As Usual (TAU) medication management for symptoms experienced by veterans receiving rehabilitation therapy for mild traumatic brain injury (mTBI) and comorbid symptoms of posttraumatic stress disorder (PTSD).
Official title: A Randomized Clinical Trial of Quetiapine to Reduce Post Concussive Syndrome Polypharmacy
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
146
Start Date
2024-07-09
Completion Date
2028-06
Last Updated
2025-07-11
Healthy Volunteers
No
Conditions
Interventions
Quetiapine Fumarate
Quetiapine is an atypical antipsychotic approved by the FDA for the treatment of schizophrenia, bipolar disorder, and as an adjunct to treat major depression. It has a broad spectrum of actions at dopaminergic (D1, D2, D3 and D4), serotonergic (5-HT2A, 5-HT2C and 5-HT7), adrenergic (α1), histaminic (H1) and muscarinic (mACh), and partial agonist at 5-HT1A receptors.
TAU
Standard of care psychotropic medications for treatment of patients with mTBI.
Locations (2)
New Mexico VA Healthcare System
Albuquerque, New Mexico, United States
South Texas Veterans Healthcare System
San Antonio, Texas, United States